Company story
We Made Inositol the Language of Health and Care.
Rooted in Italian science, dedicated to improving lives and health across the world.
Founded in Rome, Italy, Lo.Li. Pharma was established with the mission of advancing women’s health through the research, development, and distribution of innovative products supporting women at every stage of life. Guided by scientific rigor and deep expertise in female physiology, the company is led by its founder, Professor Vittorio Unfer, MD—renowned gynecologist, world-leading authority on inositols, co-founder of the Experts Group on Inositol in Basic and Clinical Research (EGOI), and author of over 200 scientific publications that have reshaped the understanding of PCOS, insulin resistance, and gestational diabetes, translating molecular science into meaningful clinical practice. Through close collaboration with universities, hospitals, and research centers in Italy and worldwide, Lo.Li. Pharma’s Ph.D. scientific team conducts extensive research programs regularly presented at major international congresses, including ESHRE and ISGE. In a market often characterized by limited clinical evidence, almost all Lo.Li. Pharma International products are supported by clinical trials published in peer-reviewed journals and presented at international scientific meetings, ensuring credibility, safety, and trust. Supported by a strong R&D team, the company excels in launching first-in-class products in new markets, developing robust scientific content aligned with the latest clinical evidence and ensuring continuous dissemination of scientific updates.
The first clinical study on Inofolic® was published in Gynecological Endocrinology. This landmark research demonstrated that the combination of myo-inositol and folic acid could effectively restore ovulation in women with Polycystic Ovary Syndrome (PCOS), marking the scientific foundation for the clinical development of Inofolic®. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction - P…
Lo.Li. Pharma began its international expansion by establishing strategic collaborations with partners in South Africa, Bulgaria, and several other countries, marking the first step toward bringing its innovative approach to women’s healthcare to a global scale.
Lo.Li. Pharma introduced the combined use of myo-inositol and D-chiro-inositol for the management of PCOS. This innovation translated emerging clinical evidence into a targeted nutritional approach, designed to support both metabolic and hormonal balance in women with PCOS.
The growing number of international partnerships led to the establishment of Lo.Li. Pharma International, a company specifically dedicated to developing and expanding Lo.Li. Pharma’s presence in global markets.
Lo.Li. Pharma launched Inofolic® HP, introducing alpha-lactalbumin to enhance myo-inositol bioavailability. This advancement addressed reduced intestinal absorption in selected patients, representing an important step toward more personalized and evidence-based nutritional support.
To reinforce its foothold in the United States, Lo.Li. Pharma founded Lo.Li. Pharma USA, with the goal of expanding market presence and exploring new strategic business opportunities.
Lo.Li. Pharma’s products are now distributed in more than 70 countries across the globe, confirming the brand’s international reach and reputation.